Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 332

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 332
---
 its permitted pledgees,
donees, transferees, assignees, successors, designees, successors-in-interest and others who later come to hold any of the Selling Shareholder’s
interest in the securities in accordance with the terms of the applicable agreements governing their respective registration rights, other
than through a public sale. This prospectus also covers any additional securities that may become issuable by reason of stock splits,
stock dividends or other similar transactions.

For additional information
regarding the issuance of the securities covered by this prospectus, see the section entitled “Committed Equity Financing”
above. We are registering the securities pursuant to the provisions of the Purchase Agreement and the Registration Rights Agreement in
order to permit the Selling Shareholder to offer the shares for resale from time to time. Except for the transactions contemplated by
the Purchase Agreement and the Registration Rights Agreement or as otherwise set forth in this prospectus, the Selling Shareholder has
not had any material relationship with us within the past three years.

The table below presents information
regarding the Selling Shareholder and the securities that it may offer from time to time under this prospectus. This table is prepared
based on information supplied to us by the Selling Shareholder, and reflects holdings as of January 14, 2025. The number of shares in
the column “Maximum Number of Ordinary Shares to be Offered Pursuant to this Prospectus” represents all of the Ordinary Shares
(represented by Depositary Shares) that the Selling Shareholder may offer under this prospectus. The Selling Shareholder may sell some,
all or none of its shares in this offering. We do not know how long the Selling Shareholder will hold the shares before selling them,
and we currently have no agreements, arrangements or understandings with the Selling Shareholder regarding the sale of any of the shares.

Beneficial ownership is determined
in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which
the Selling Shareholder have voting and investment power. The percentage of Ordinary Shares beneficially owned by the Selling Shareholder
following the offering shown in the table below is based on an aggregate of 6,685,918,922 Ordinary Shares outstanding on January 15, 2025.
Because the purchase price of the Depositary Shares issuable under the Purchase Agreement is determined on each Fixed Purchase Date, with
respect to a Fixed Purchase, on the applicable VWAP Purchase Date, with respect to